Andrew Harkin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2267085/publications.pdf

Version: 2024-02-01

		76326	106344
122	4,856	40	65
papers	citations	h-index	g-index

143	143	143	6480
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology, 2012, 92, 959-975.	3.3	293
2	Nitric oxide synthase inhibitors have antidepressant-like properties in mice. European Journal of Pharmacology, 1999, 372, 207-213.	3.5	202
3	Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-Î³?. Neuroscience Letters, 2008, 441, 29-34.	2.1	180
4	Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain, Behavior, and Immunity, 2013, 28, 170-181.	4.1	173
5	Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology, 2013, 228, 157-166.	3.1	149
6	Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology, 2004, 14, 274-281.	0.7	148
7	Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology, 2003, 44, 616-623.	4.1	137
8	Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. International Journal of Neuropsychopharmacology, 2009, 12, 687.	2.1	122
9	DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamicâ€“pituitaryâ€“adrenal axis activity and to early life emotional abuse. Psychiatry Research, 2018, 265, 341-348.	3.3	120
10	Gutâ€“brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatrica, 2018, 30, 275-296.	2.1	118
11	Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders. Neuropharmacology, 2017, 112, 307-323.	4.1	105
12	A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clinical Neuroscience Research, 2003, 3, 253-262.	0.8	91
13	Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain, Behavior, and Immunity, 2012, 26, 979-987.	4.1	90
14	Effect of Subchronic Antidepressant Treatments on Behavioral, Neurochemical, and Endocrine Changes in the Forced-Swim Test. Pharmacology Biochemistry and Behavior, 2000, 65, 591-597.	2.9	86
15	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. European Journal of Pharmacology, 1999, 364, 123-132.	3.5	85
16	Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. Journal of Psychopharmacology, 2002, 16, 115-123.	4.0	85
17	Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neuroscience Letters, 2005, 374, 142-146.	2.1	85
18	C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain, Behavior, and Immunity, 2013, 34, 108-119.	4.1	81

#	Article	IF	Citations
19	Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. Physiology and Behavior, 2000, 69, 531-539.	2.1	80
20	Olfactory Bulbectomy Provokes a Suppression of Interleukin-1Î² and Tumour Necrosis Factor-Î± Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine Treatment. NeuroImmunoModulation, 2000, 7, 27-35.	1.8	79
21	Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. International Journal of Neuropsychopharmacology, 2014, 17, 917-928.	2.1	76
22	Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry, 2007, 190, 112-117.	2.8	75
23	Noradrenaline acting at Î²-adrenoceptors induces expression of IL-1Î² and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology, 2010, 59, 37-48.	4.1	72
24	Acute stress suppresses pro-inflammatory cytokines TNF-Î± and IL-1Î² independent of a catecholamine-driven increase in IL-10 production. Journal of Neuroimmunology, 2005, 159, 119-128.	2.3	70
25	Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain, Behavior, and Immunity, 2015, 48, 274-286.	4.1	70
26	Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology, 2018, 95, 8-17.	2.7	69
27	Chronic Fluoxetine Treatment Attenuates Stressor-Induced Changes in Temperature, Heart Rate, and Neuronal Activation in the Olfactory Bulbectomized Rat. Neuropsychopharmacology, 2007, 32, 1312-1320.	5.4	68
28	The PSD-95/nNOS complex: New drugs for depression?. , 2012, 133, 218-229.		68
29	Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice. Neuropsychopharmacology, 2013, 38, 1575-1584.	5.4	65
30	Noradrenaline acting at central Î²-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration. Brain, Behavior, and Immunity, 2010, 24, 660-671.	4.1	58
31	Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. Journal of Neuroimmunology, 2010, 220, 34-42.	2.3	57
32	Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (â€œEcstasyâ€) and MDA (â€œLoveâ€). Neuropharmacology, 2006, 50, 69-80.	4.1	56
33	The Î²2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. Brain, Behavior, and Immunity, 2010, 24, 1354-1361.	4.1	56
34	Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. European Journal of Pharmacology, 1999, 379, 125-133.	3.5	54
35	A study of VitalViewâ„¢ for behavioural and physiological monitoring in laboratory rats. Physiology and Behavior, 2002, 77, 65-77.	2.1	54
36	Stress-Related Immune Markers in Depression: Implications for Treatment. International Journal of Neuropsychopharmacology, 2016, 19, pyw001.	2.1	53

#	Article	IF	Citations
37	Caffeine provokes adverse interactions with 3,4â€methylenedioxymethamphetamine (MDMA, â€˜ecstasyâ€™) and related psychostimulants: mechanisms and mediators. British Journal of Pharmacology, 2012, 167, 946-959.	5.4	52
38	Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder. International Journal of Molecular Sciences, 2017, 18, 2226.	4.1	49
39	Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3â€Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferonâ€Positive Primary SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1688-1699.	5.6	45
40	Noradrenaline acting on astrocytic Î²2-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology, 2014, 77, 234-248.	4.1	44
41	Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology, 1999, 145, 303-308.	3.1	42
42	Characterization of d-fenfluramine-induced hypothermia: evidence for multiple sites of action. European Journal of Pharmacology, 2000, 390, 275-285.	3.5	36
43	Mechanisms mediating the ability of caffeine to influence MDMA (â€˜Ecstasyâ€™)â€induced hyperthermia in rats. British Journal of Pharmacology, 2010, 160, 860-877.	5.4	36
44	Persistent central inflammation and region specific cellular activation accompany depression- and anxiety-like behaviours during the resolution phase of experimental colitis. Brain, Behavior, and Immunity, 2019, 80, 616-632.	4.1	35
45	Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sciences, 2001, 68, 1367-1382.	4.3	33
46	Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. Brain, Behavior, and Immunity, 2020, 83, 153-162.	4.1	33
47	Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease. Neural Regeneration Research, 2018, 13, 1332.	3.0	33
48	Adenosine A1 Receptor Blockade Mimics Caffeine's Attenuation of Ethanol-Induced Motor Incoordination. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 299-304.	2.5	32
49	Methylenedioxymethamphetamine Suppresses Production of the Proinflammatory Cytokine Tumor Necrosis Factor-Î± Independent of a Î²-Adrenoceptor-Mediated Increase in Interleukin-10. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 134-143.	2.5	32
50	Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology, 2001, 154, 177-188.	3.1	31
51	A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test. Pharmacology Biochemistry and Behavior, 2010, 94, 524-533.	2.9	31
52	Pharmacological targeting of Î²₂â€adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease. British Journal of Pharmacology, 2020, 177, 282-297.	5.4	31
53	Association between psychological measures with inflammatory anddisease-related markers of inflammatory bowel disease. International Journal of Psychiatry in Clinical Practice, 2017, 21, 221-230.	2.4	28
54	Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1. Frontiers in Neuroscience, 2015, 9, 428.	2.8	27

#	Article	IF	Citations
55	Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity. European Neuropsychopharmacology, 1999, 9, 165-170.	0.7	26
56	Amygdala substructure volumes in Major Depressive Disorder. NeuroImage: Clinical, 2021, 31, 102781.	2.7	26
57	Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. European Journal of Pharmacology, 2017, 810, 163-173.	3.5	25
58	Caffeine induces a profound and persistent tachycardia in response to MDMA (â€œEcstasyâ€) administration. European Journal of Pharmacology, 2007, 555, 194-198.	3.5	24
59	Methylenedioxymethamphetamine-induced suppression of interleukin-1Î² and tumour necrosis factor-Î± is not mediated by serotonin. European Journal of Pharmacology, 2001, 418, 147-152.	3.5	23
60	Stimulation of central Î²2-adrenoceptors suppresses NFÎºB activity in rat brain: A role for IÎºB. Neurochemistry International, 2013, 63, 368-378.	3.8	22
61	Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression. European Neuropsychopharmacology, 2014, 24, 1349-1361.	0.7	22
62	Acute neuroinflammation, sickness behavior and working memory responses to acute systemic LPS challenge following noradrenergic lesion in mice. Brain, Behavior, and Immunity, 2021, 94, 357-368.	4.1	22
63	Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. European Journal of Neuroscience, 2003, 18, 1021-1027.	2.6	21
64	Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the Î±2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2018, 69, 456-469.	4.1	21
65	Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA (â€˜ecstasyâ€™). Psychopharmacology, 2010, 211, 15-25.	3.1	20
66	Glial fibrillary acidic protein (GFAP) immunoreactivity correlates with cortical perfusion parameters determined by bolus tracking arterial spin labelling (bt-ASL) magnetic resonance (MR) imaging in the Wistar Kyoto rat. Physiology and Behavior, 2016, 160, 66-79.	2.1	20
67	Test Conditions Influence the Response to a Drug Challenge in Rodents. Pharmacology Biochemistry and Behavior, 2000, 65, 389-398.	2.9	19
68	Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and Î²1-adrenergic receptors in an animal model of depression. Journal of Neural Transmission, 2000, 107, 1213-1227.	2.8	19
69	A role for adenosine A1 receptor blockade in the ability of caffeine to promote MDMA â€œEcstasyâ€•induced striatal dopamine release. European Journal of Pharmacology, 2011, 650, 220-228.	3.5	19
70	Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. International Journal of Neuropsychopharmacology, 2014, 17, 1477-1486.	2.1	19
71	Expression of glucocorticoid inducible genes is associated with reductions in cornu ammonis and dentate gyrus volumes in patients with major depressive disorder. Development and Psychopathology, 2014, 26, 1209-1217.	2.3	19
72	Physiological and behavioral responses to stress: what does a rat find stressful?. Lab Animal, 2002, 31, 42-50.	0.4	18

#	Article	IF	Citations
73	A Toxicokinetic Study of Nickelâ€induced Immunosuppression in Rats. Immunopharmacology and Immunotoxicology, 2003, 25, 655-670.	2.4	17
74	Recent Advances in Translational Magnetic Resonance Imaging in Animal Models of Stress and Depression. Frontiers in Cellular Neuroscience, 2017, 11, 150.	3.7	17
75	L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents. Behavioural Brain Research, 2019, 362, 90-102.	2.2	17
76	Reduced efficacy of fluoxetine following MDMA (â€œEcstasyâ€)-induced serotonin loss in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1894-1901.	4.8	16
77	Muscling In on Depression. New England Journal of Medicine, 2014, 371, 2333-2334.	27.0	14
78	Amitriptyline protects against <scp>TNF</scp>â€Î±â€induced atrophy and reduction in synaptic markers via a Trkâ€dependent mechanism. Pharmacology Research and Perspectives, 2016, 4, e00195.	2.4	14
79	The Î²₂-adrenoceptor agonist clenbuterol reduces the neuroinflammatory response, neutrophil infiltration and apoptosis following intra-striatal IL-1Î² administration to rats. Immunopharmacology and Immunotoxicology, 2018, 40, 99-106.	2.4	14
80	The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment. European Journal of Pharmacology, 1998, 346, 15-21.	3.5	13
81	Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity. Behavioural Brain Research, 2017, 316, 18-28.	2.2	13
82	Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy. Journal of ECT, 2019, 35, 115-121.	0.6	13
83	Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice. NeuroImmunoModulation, 2016, 23, 137-150.	1.8	12
84	Lâ€alphaâ€aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinsonâ€™s disease in male rats. Journal of Neuroscience Research, 2019, 97, 804-816.	2.9	12
85	Blood plasma B vitamins in depression and the therapeutic response to electroconvulsive therapy. Brain, Behavior, & Immunity - Health, 2020, 4, 100063.	2.5	12
86	Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. Neuroscience, 2015, 301, 421-438.	2.3	10
87	Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors. European Journal of Pharmacology, 2000, 389, 187-192.	3.5	8
88	Clenbuterol activates the central IL-1 system via the Î²2-adrenoceptor without provoking inflammatory response related behaviours in rats. Brain, Behavior, and Immunity, 2016, 56, 114-129.	4.1	8
89	Regional Specific Modulation of Stress-Induced Neuronal Activation Associated with the PSD95/NOS Interaction Inhibitor ZL006 in the Wistar Kyoto Rat. International Journal of Neuropsychopharmacology, 2017, 20, 833-843.	2.1	8
90	Dexamethasone attenuates inflammatory-mediated suppression of Î²2-adrenoceptor expression in rat primary mixed glia. Journal of Neuroimmunology, 2020, 338, 577082.	2.3	8

#	Article	IF	Citations
91	Dopamine D₁ Receptorâ€Mediated Intracellular Responses in the Hypothalamus after Coâ€Administration of Caffeine with MDMA. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 283-289.	2.5	6
92	<scp>MDMA</scp> â€˜ecstasyâ€™ increases cerebral cortical perfusion determined by bolusâ€tracking arterial spin labelling (<scp>btASL</scp>) <scp>MRI</scp>. British Journal of Pharmacology, 2013, 169, 974-987.	5.4	6
93	Novel Targets in the GlutamateÂand Nitric Oxide Neurotransmitter Systems for the Treatment of Depression. , 2016, , 81-113.		6
94	Inhibitors of the NMDA-Nitric Oxide Signaling Pathway Protect Against Neuronal Atrophy and Synapse Loss Provoked by l-alpha Aminoadipic Acid-treated Astrocytes. Neuroscience, 2018, 392, 38-56.	2.3	5
95	Investigation of the mechanisms mediating MDMA â€œEcstasyâ€•induced increases in cerebro-cortical perfusion determined by btASL MRI. Psychopharmacology, 2015, 232, 1501-1513.	3.1	4
96	Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). Pilot and Feasibility Studies, 2016, 2, 38.	1.2	3
97	Rodent Models of Stress-Induced Depression: The Link Between Stress and Immune System Related Changes. Current Topics in Neurotoxicity, 2015, , 33-62.	0.4	3
98	Regulation of Î²₂-adrenoceptors in brain glia: implications for neuroinflammatory and degenerative disorders. Neural Regeneration Research, 2020, 15, 2035.	3.0	3
99	Corrigendum to: â€œNoradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptorsâ€•[Eur. J. Pharmacol. 389 (2000) 187â€“192]. European Journal of Pharmacology, 2000, 397, 399.	3.5	2
100	Association of maternal emotional abuse with decreased serotonin transporter gene (SLC6A4) methylation. European Neuropsychopharmacology, 2016, 26, S177.	0.7	2
101	Editorial: Biology of Brain Disorders. Frontiers in Cellular Neuroscience, 2017, 11, 366.	3.7	2
102	Kynurenic Acid Protects Against Reactive Glial-associated Reductions in the Complexity of Primary Cortical Neurons. Journal of NeuroImmune Pharmacology, 2021, 16, 679-692.	4.1	2
103	Comparison of kynurenine pathway activation and tryptophan depletion induced by activation of human T-cells and innate immune cells. Brain, Behavior, and Immunity, 2011, 25, S208-S209.	4.1	1
104	The anti-inflammatory actions of noradrenergic agents as a target to prevent neurodegeneration in Parkinson's disease. Journal of Neuroimmunology, 2014, 275, 122-123.	2.3	1
105	Noradrenaline-mediated protection against TNF-alpha-induced neuronal atrophy. Journal of Neuroimmunology, 2014, 275, 167.	2.3	1
106	AB0186â€…Elevated Indoleamine-2,3-Dioxygenase (IDO) and Tryptophan Catabolism in Primary SjÃ–gren's Syndrome Patients, Positive for the Interferon Type I Signature: A Possible Link to Fatigue and Depression. Annals of the Rheumatic Diseases, 2014, 73, 864.2-864.	0.9	1
107	P.1.d.002 A role for glial-associated kynurenine pathway activation in modulating neuronal outgrowth and complexity. European Neuropsychopharmacology, 2015, 25, S206-S207.	0.7	1
108	PBMC telomerase activity in depression and the response to electroconvulsive therapy. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1297-1307.	3.2	1

#	Article	IF	Citations
109	47. Noradrenaline re-uptake inhibition influences neuroinflammatory and degenerative changes associated with the excitotoxin kainic acid. Brain, Behavior, and Immunity, 2009, 23, S38.	4.1	0
110	107. A systemic LPS challenge does not alter central Beta2-adrenoceptor expression or reponsiveness. Brain, Behavior, and Immunity, 2009, 23, S54-S55.	4.1	0
111	A role for central IL-1beta in the suppression of locomotor activity induced the by the beta2-adrenoceptor agonist clenbuterol?. Brain, Behavior, and Immunity, 2010, 24, S2-S3.	4.1	0
112	The NOD mouse model for immune induced depressive-like behavior. Brain, Behavior, and Immunity, 2010, 24, S50-S51.	4.1	0
113	The effect of antidepressants on inflammatory markers in animal models of depression. European Psychiatry, 2011, 26, 2091-2091.	0.2	0
114	149. Poly I:C-induced activation of the innate immune response is accompanied by symptoms of depression and anxiety. Brain, Behavior, and Immunity, 2011, 25, S222.	4.1	0
115	150. Stimulation of central Î²2-adrenoceptors suppresses NF-ÎºB activity in hippocampus and cortex: A role for IÎºB. Brain, Behavior, and Immunity, 2011, 25, S222.	4.1	0
116	Astrocytic dysfunction induced by l-alphaaminoadipic acid reduces measures of neuronal complexity in vitro; rescue by NMDA receptor antagonists. Journal of Neuroimmunology, 2014, 275, 127-128.	2.3	0
117	P.1.f.015 Evidence for central molecular changes and changes to neuronal activity in an animal model of inflammatory bowel disease. European Neuropsychopharmacology, 2015, 25, S233-S234.	0.7	0
118	P.4.011 L-Î±-Aminoadipic acid provokes a reduction of astrocytes in the prelimbic cortex and depressive-like behaviour in mice. European Neuropsychopharmacology, 2016, 26, S94-S95.	0.7	0
119	Evaluation of NMDA signalling modifiers as putative antidepressants in animal models. European Neuropsychopharmacology, 2016, 26, S120.	0.7	0
120	A gut instinct for kynurenic acid. Brain, Behavior, and Immunity, 2019, 79, 16-17.	4.1	0
121	Ketamine and depression: A special kase for kynurenic acid?. Brain, Behavior, and Immunity, 2019, 75, 10-11.	4.1	0
122	A combined and comparative study of physiologic and behavioral parameters in a systemic toxicity test. Contemporary Topics in Laboratory Animal Science, 2003, 42, 31-8.	0.2	0